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ABSTRACT.  
CYP2D6, a cytochrome P450 (CYP) enzyme, metabolises codeine to morphine. Within the 
human body, 0-15% of codeine undergoes O-demethylation by CYP2D6 to form morphine, a 
far stronger analgesic than codeine. Genetic polymorphisms in wild-type CYP2D6 (CYP2D6-
wt) are known to cause poor to extensive metabolism of codeine and other CYP2D6 substrates. 
We have established a platform technology that allows stable expression of human CYP genes 
from chromosomal loci of baker’s yeast cells. Four CYP2D6 alleles, (i) chemically-synthesized 
CYP2D6.1, (ii) chemically-synthesized CYP2D6-wt, (iii) chemically-synthesized CYP2D6.10, 
and (iv) a novel CYP2D6.10 variant CYP2D6-C (i.e. CYP2D6.10A122V) isolated from a liver 
cDNA library, were cloned for chromosomal integration in yeast cells. When expressed in 
yeast, CYP2D6.10 enzyme shows weak activity compared with CYP2D6-wt and CYP2D6.1 
which have moderate activity, as reported earlier. Surprisingly however, CYP2D6-C enzyme is 
far more active than CYP2D6.10. More surprisingly, although CYP2D6.10 is a known low 
metabolizer of codeine, yeast cells expressing CYP2D6-C transform >70% of codeine to 
morphine, which is more than twice than cells expressing the extensive metabolizers, 
CYP2D6.1 and CYP2D6-wt. The latter two enzymes predominantly catalyse formation of 
codeine’s N-demethylation product, norcodeine, with >55% yield. Molecular modelling studies 
explain the specificity of CYP2D6-C for O-demethylation, validating observed experimental 
results. The yeast-based CYP2D6 expression systems, described here, could find generic use in 
CYP2D6-mediated drug metabolism and also in high-yield chemical reactions that allow 
formation of regio-specific dealkylation products.  
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INTRODUCTION 
Xenobiotics are chemicals that are foreign to the human body and are considered harmful and 
toxic if they were retained permanently within the body. Endobiotics, in contrast, are 
endogenous chemicals which have important functional roles in the body. The human 
cytochrome P450 (CYP) family of enzymes, belonging to a superfamily of heme-thiolate 
proteins that are present in all living genera of organisms, catalyse the biotransformation (i.e. 
metabolism) of a diverse range of xenobiotics and endobiotics in humans.1  
There are 57 human CYP genes which are differentially expressed in diverse tissues. The 12-
15 human CYP enzymes, which metabolise 75% of all approved drugs (i.e. pharmaceuticals), 
are naturally bound to the liver’s intracellular endoplasmic reticular membranes. Hence, the 
enzyme activities of these CYPs are expressed within liver cells. Among the hepatic CYPs that 
are involved in drug metabolism, the enzymes that play the most important roles are CYPs 1A2, 
3A4, 2C9, 2C19, 2D6 and 2E1, metabolizing over 90% of all drugs in the urine that undergo 
CYP-mediated biotransformation. Although CYP2D6 is only 2-4% of the total CYP content in 
the liver, it is responsible for the metabolism of at least 25-30% of currently approved 
pharmaceuticals.2  
Genetic polymorphisms in a CYP gene can significantly alter the corresponding CYP 
enzyme’s ability to metabolise drugs. It has widely been reported that the gene coding for the 
CYP2D6 protein is highly polymorphic and has more than 100 alleles 
(http://www.cypalleles.ki.se/cyp2d6.htm). Extensive studies on the effects of CYP2D6 genetic 
polymorphisms in the metabolism of drugs, that are substrates of the CYP2D6 enzyme, have led 
to the conclusion that polymorphisms in the CYP2D6 gene can lead to poor (i.e. null), low, and 
extensive (i.e. normal) metabolizer phenotypes.3 Individuals who are poor metabolizers carry a 
non-functional CYP2D6 gene, incapable of producing an active enzyme. This is either because 
there are deletions in the genetic sequence or there are nucleotide substitutions that translate to a 
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non-functional truncated protein. Across dissimilar ethnic groups, the percentages of individuals 
carrying the CYP2D6 gene with poor, low or extensive metabolizer phenotypes vary.4 For 
instance, as high as 7.7% of the Caucasian population has no CYP2D6 activity (i.e. are poor 
metabolizers) whereas less than 1% lack CYP2D6 activity amongst the Chinese, Japanese and 
South Indian people.4-5 However, even in populations which are generally classified as CYP2D6 
extensive metabolizers, there is a noticeable variation in metabolic capability. Although the 
percentage of individuals with poor CYP2D6 metabolizer phenotype is low in the Chinese, 
Japanese and South Indian population,4-5 surprisingly, on average, they generally exhibit lower 
CYP2D6 activity than Caucasians who carry the extensive metaboliser allele, CYP2D6.1 
(http://www.cypalleles.ki.se/cyp2d6.htm). The CYP2D6.1 protein has one change in amino 
acid, Met374Val, with respect to the wild-type allele which is referred here as CYP2D6-wt.6 
The Met has been replaced by Val at position 374 in 2D6.1 (i.e. it has Met374Val change in its 
sequence with respect to the wt).7  
The observed overall decrease in CYP2D6 activity, in Asian populations, is manifested as an 
increase in metabolic ratio (i.e. ratio of parent compound/ metabolite) for several approved 
drugs that are known to be CYP2D6 substrates, such as debrisoquine, sparteine, metoprolol, and 
dextromethorphan.2a It has been suggested that CYP2D6 activity diminishes in Asian 
populations primarily because of the prevalence of the low metabolizer allele, CYP2D6.10 
(http://www.cypalleles.ki.se/cyp2d6.htm), which has appreciably less enzymatic activity than 
the extensive metabolisers CYP2D6-wt and CYP2D6.1. CYP2D6.10 is present in around 73% 
of Taiwanese Chinese,8 56% of mainland Chinese,9 45% of Koreans,10 39% of Iranians,11 38% 
of Japanese,12 and 10.2% of South Indians.5b The frequency of the CYP2D6.10 allele occurring 
in populations other than Asians is remarkably low from 1-5% in Caucasians,13 around 2.7% in 
African Americans14 and 2.8% in Mexican Americans.15 The low metabolizer CYP2D6.10 
allele codes for a protein that has the amino acid substitutions Pro34Ser and Ser486Thr when 
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aligned with the CYP2D6.1 protein sequence, and the amino acid substitutions Pro34Ser, 
Met374Val and Ser486Thr when aligned with CYP2D6-wt 
(http://www.cypalleles.ki.se/cyp2d6.htm).  
Codeine and morphine are analgesics of the opiate family. However, morphine has 200-fold 
greater affinity as an agonist for the µ-opioid receptors, the mediators of nullifying pain, 
compared to codeine.16 Both drugs are found naturally in the poppy plant, Papaver 
somniferum,17 with morphine being much more abundant than codeine. Since the CYP2D6 
enzyme in the human liver can naturally transform codeine to morphine, codeine is considered a 
safer alternative, to the direct use of morphine, in an outpatient setting.1b For commercial use, 
codeine is, therefore, synthesized from morphine.18 It has been reported that, within the human 
body, depending on the CYP2D6 polymorphism, 0-15% of codeine is O-demethylated to 
morphine, codeine’s most active metabolite.1b, 19 The biotransformation reaction of codeine to 
morphine has been extensively studied using CYP2D6 enzymes that are encoded by diverse 
CYP2D6 polymorphic alleles. Pain relief is inadequate in individuals who carry a poor 
metabolizer incapable of synthesizing morphine, whereas individuals with a low metabolizer, 
such as CYP2D6.10, are substantially less efficient at synthesizing endogenous morphine than 
the extensive metabolizers.20  
Herein, we report the metabolic study of codeine using four CYP2D6 alleles expressed 
within recombinant baker’s yeast cells: (i) CYP2D6-wt which bears Methionine (M) at position 
374;6 (ii) CYP2D6.1 which bears Valine (V) at position 374 instead of Met which is in 
CYP2D6-wt (http://www.cypalleles.ki.se/cyp2d6.htm); (iii) CYP2D6.10 which bears Serine 
(S), V and Threonine (T) at positions 34, 374, and 486 instead of Pro (P), Met (M) and S at the 
same positions of CYP2D6-wt (http://www.cypalleles.ki.se/cyp2d6.htm); and (iv) a novel 
CYP2D6.10 variant, CYP2D6-C, which bears V at position 122 instead of Alanine (A) present 
in CYP2D6.10. Surprisingly, we find that CYP2D6-C is a far superior metaboliser of codeine to 
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morphine than either CYP2D6-wt or CYP2D6.1, although CYP2D6.10 is a known low 
metabolizer of codeine.20 The cDNA coding for the variant was isolated from a human liver 
cDNA library (constructed by GATC Biotech, Germany). Fortuitously, it was found out later 
that the isolated cDNA was identical to the clone TC104446 distributed by Origene (Rockville, 
Maryland, USA), purportedly as the wild-type CYP2D6 gene. The experimental results 
obtained have been validated via molecular modelling. The chemical structures of codeine and 
its metabolites, that have been identified in the human organism, are shown in Figure 1.  
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Figure 1. Chemical structures of codeine and its metabolites.  
 
RESULTS AND DISCUSSION 
CYP enzymes are known for their exceptional ability to carry out diverse sets of chemical 
reactions, for example, hydroxylation, epoxidation or demethylation, in a stereo-selective and 
regio-selective manner, both in plants and humans. The human liver CYP enzymes, involved in 
drug metabolism, are naturally bound to the intracellular endoplasmic reticular (ER) 
membranes. Loss of membrane integrity results in complete loss of CYP enzymatic activity. It 
is, therefore, essential that, for heterologous expression of human CYPs in recombinant 
organisms, they are integrated into the ER membranes so that their native activity is manifested. 
The intracellular architecture of eukaryotic baker’s yeast (Saccharomyces cerevisiae) cells and 
human cells is alike. Since yeast and human cells also possess structurally similar ER 
membranes, it would be expected that human CYPs expressed in yeast would closely resemble 
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in function the CYP enzymes present in human cells. This would not be the case for human 
CYPs expressed in bacterial (Escherichia coli) cells since they are prokaryotic and, therefore, 
do not possess any ER membranes.  
We have created a platform technology that allows stable expression, in baker’s yeast, of 
human CYP genes from yeast’s different chromosomal loci. The ability of four CYP2D6 variant 
enzymes to transform codeine to morphine was compared using this technology. The four 
alleles, which produced active enzymes in yeast, were CYP2D6.1, CYP2D6-wt, CYP2D6.10 
and CYP2D6-C. The CYP2D6.1, CYP2D6-wt and CYP2D6.10 genes were chemically 
synthesized (by Genewiz, USA) whereas CYP2D6-C was isolated from a human liver cDNA 
library (obtained from GATC Biotech, Germany). Comparisons of the amino acid sequences of 
the four variant proteins are shown in Figures S1A-B of Supporting Information.  
Cloning of CYP2D6 Allelic Genes, Transformation and Growth of Yeast Cells and 
Determination of Cellular CYP2D6 Enzyme Activities. Extrachromosomal 2-micron (2 µ) 
plasmids are normally used for expression of heterologous (i.e. human) proteins in yeast.21 
Unfortunately, a 2 µ plasmid can be maintained within yeast cells only when grown in selective 
synthetic defined (SD) minimal medium.22 Since such medium lack essential nutrients, a CYP 
gene expression cassette borne on a 2 µ plasmid would produce very little CYP protein/enzyme 
simply because of poor yeast cell growth. As an alternative, complete full YPD medium 
(containing yeast extract, peptone, dextrose/ glucose), which cannot select for the presence of a 
2 µ plasmid, could be used for short term growth of cells which bear a CYP gene expression 
cassette on a 2-micron plasmid. However, over a time period of 24-48 h, there would be a huge 
loss of plasmid from the cells, resulting in yeast cells continuing to grow in the absence of the 2 
µ plasmid that bears the heterologous human CYP gene.  
In order to maximise production of human CYP proteins within yeast cells, we have 
established a platform technology that creates stable yeast strains which can be grown in 
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complete nutritious, non-selective YPD medium, over many days even weeks, without any loss 
of genetic information pertaining to the heterologous human CYP genes. Stable yeast strains 
were created by integrating copies of CYP2D6 gene expression cassettes into yeast cells’ 
different chromosomal loci, namely for this investigation, at the HIS3 (on chromosome XV) and 
URA3 (on chromosome V) loci, via homologous recombination.23 Chromosomal integration of 
CYP gene expression cassettes would allow stable propagation of the cells’ genetic information 
during cell division, in YPD medium. Thus, it would permit yeast cells containing integrated 
copies of human CYP gene expression cassettes to be used routinely for (i) diverse 
biotransformation reactions using live whole cells and (ii) production, on a large scale, of active 
human CYP enzymes which closely mimic the human enzymes in the liver.  
For driving expression of human CYP genes in yeast, the ADH2 promoter (ADH2p; 
Saccharomyces Genome Database; YMR303C) was used. The ADH2p is repressed in glucose-
containing medium and is induced by ethanol. The ADH2 promoter is gradually induced 
through steady conversion of glucose, present in the yeast cell culture medium, to ethanol. Thus, 
yeast cells slowly adapt to overexpression of the toxic, heterologous human CYP enzymes 
which have strong oxidoreductive properties.24 The transcription termination signal that was 
used for expression of human CYP genes in yeast was the SUC2 terminator (SUC2t; 
Saccharomyces Genome Database; S000001424). Both ADH2p and SUC2t were isolated by the 
polymerase chain reaction (PCR) using genomic DNA isolated from the wild-type yeast strain 
S288C (ATCC 204508) as template and DNA-specific primers.  
Four pairs of integrative plasmids, bearing the four CYP2D6 alleles on plasmids encoding 
the HIS3 or URA3 genes (Figures S2 A and B), were created for use in integration into the yeast 
strain YY7, derived from the strain W303-1a (ATCC 208352) which already contained a 
modified human CYP450 reductase (CPR) gene.25 The plasmids were integrated at the HIS3 
and the URA3 chromosomal loci of the yeast strain YY7. Episomal plasmids, bearing the URA3 
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gene as selection marker and encoding the four different CYP2D6 alleles, were also constructed 
(Figures S2 C and D). Corresponding strains containing these plasmids were created for sake of 
comparison with yeast strains that contain integrative copy/copies of CYP2D6 gene expression 
cassettes.  Figure 2A-B shows a comparison of CYP2D6 activities obtained from yeast strains 
containing expression cassettes for the CYP2D6-wt and CYP2D6.1 alleles, integrated at the 
HIS3 chromosomal locus or borne on an episomal plasmid. The results in Figures 2A-B clearly 
indicate that, over an identical period of time, a copy of either of the two CYP2D6 alleles, 
CYP2D6-wt and CYP2D6.1, integrated at the HIS3 chromosomal locus produces far more 
CYP2D6 enzyme activity than from an extra-chromosomal episomal plasmid. It could be 
inferred that this was primarily because of the stability of the integrated copy of the CYP2D6 
gene expression cassettes during expression of the protein. Similar results were obtained for the 
other two CYP2D6 alleles, CYP2D6.10 and CYP2D6-C. This is shown in Figures S3 (A), (B) 
and Figures S4 (A), (B), in Supporting Information.  
Two copies of each of the four CYP2D6 alleles, CYP2D6-wt, CYP2D6.1, CYP2D6.10 and 
CYP2D6-C, were then integrated at the HIS3 and URA3 loci of the yeast strain YY7 that 
already contained a modified human CPR.25 The enzyme activities produced by these strains 
after 18 h of culture were determined, as described in Experimental Procedures. Using EOMCC 
as a fluorogenic substrate, comparison of the enzymatic activities of the four CYP2D6 proteins, 
encoded by the four different alleles, are depicted in Figures 2 C and D. The results show that 
CYP2D6.10 possesses the weakest enzymatic activity and that CYP2D6-C has ~8-fold more 
activity than CYP2D6.10, a known CYP2D6 low metabolizer allele.1a, 8-15 
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Figure 2. The graph (A) compares the kinetics of enzyme activities of the two alleles CYP2D6-wt (2D6-wt) and 
CYP2D6.1 (2D6.1), produced in the strain YY7, from gene expression cassettes either (i) integrated at the HIS3 
chromosomal locus or (ii) borne on an episomal plasmid. The kinetics of enzyme activity, present in ~1x 106 cells, 
was followed over a time course of 34 min. The concentration of the fluorogenic substrate, EOMCC, used for each 
assay was 2 µM. The amount of fluorescent product, 7-HCC, formed was monitored at each time point using a 
fluorescent plate reader. The graphs represent the average of results obtained from three independent experiments. 
The bar plot (B) mirrors the fluorescence values of the graphs in (A), at time point 32 min. The graph (C) compares 
the kinetics of enzyme activities of the four alleles CYP2D6-C (2D6-C), CYP2D6-wt (2D6-wt), CYP2D6.1 
(2D6.1) and CYP2D6.10 (2D6.10), expressed as 2 copies of each gene in the strain YY7, from the HIS3 and URA3 
chromosomal loci. The kinetics of enzyme activity, present in ~1x 106 cells, was followed over a time course of 33 
min. The concentration of the fluorogenic substrate, EOMCC, used for each assay was 2 µM. The amount of 
fluorescent product, 7-HCC, formed was monitored at each time point using a fluorescent plate reader. The graphs 
represent the average of results obtained from three independent experiments. The bar plot (D) mirrors the 
fluorescence values of the graphs in (C), at time point 32 min. The data represent mean ± S.D. of three independent 
experiments. ‘RFU’ represents relative fluorescence units. Data were assembled from three independent 
11 
 
experimental groups, and a between group ANOVA test identified significant differences (P < 0.05) between 
strains, in all comparative analyses performed. 
 
The western-blot experiment confirmed that levels of expression in yeast of the four 
CYP2D6 proteins, from the different alleles, do not vary (Figure 3A). 10 µg of total protein, 
obtained from lysis of ~1x 106 cells from each of the four strains expressing CYP2D6-wt, 
CYP2D6.1, CYP2D6.10 and CYP2D6-C alleles, were analyzed by Western blotting (Figure 
3A). The results show that roughly equal amounts of CYP2D6 protein are produced by each 
yeast strain, from the same number of cells. This would indicate that differences in the levels of 
enzymatic activities between the different alleles, seen in yeast (Figure 2C-D), are a genuine 
reflection of the allelic phenotypes.  Next, we estimated the amount of enzyme, produced within 
yeast cells, by genes coding for CYP2D6-wt, CYP2D6.1 and CYP2D6-C (CYP2D6.10A122V) 
alleles. Figure 3B-C attempts to quantify the amounts of CYP2D6 enzyme activities produced 
by a defined number of recombinant yeast cells, i.e. 1x 107 cells (approximately 1 OD600 of 
cells), harbouring the three different CYP2D6 alleles, CYP2D6-wt, CYP2D6.1 and CYP2D6-C 
(CYP2D6.10A122V). The cells were grown in YPD cultures over 54 h. The cells were provided 
with fresh YPD medium, every 18 h. It was observed that after, every 18 h of growth, 
enzymatic activity, per OD600 of cells, was gradually augmented as cell density dramatically 
increased with time (unpublished observations; ISW, PhD thesis). From Figure 3B-C, it is 
observed that the amount of CYP2D6-wt enzyme present in 1x 107 cells, that are involved in the 
metabolism of the fluorogenic substrate EOMCC to form the product 7-HCC, is equivalent to 
around 3 pmoles (picomoles) of CYP2D6 Supersomes (Corning). Similarly, 1 x 107 cells 
expressing CYP2D6-C (2D6-C) equates to around 1.5 pmoles of CYP2D6 Supersomes whereas 
the same volume of cells expressing CYP2D6.1 (2D6.1) equates to approximately 2.5 pmoles of 
CYP2D6 Supersomes.  These results would indicate that the CYP2D6 variant enzymes, 
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produced within yeast cells, may be remarkably proficient in performing biotransformation 
reactions on CYP2D6 substrates that would allow formation of products with high yields. The 
results would also indicate that with chromosomal integrations of a CYP gene, a large amount 
of microsomal enzyme, with high activity, can possibly be isolated from recombinant baker’s 
yeast. In fact, the CYP2D6-wt enzyme was obtained at ~130 nanomoles/L of yeast cell culture 
with activities that were at least 2-fold better than the three commercially available enzymes, 
Supersomes (Corning), Baculosomes (Invitrogen) and Bactosomes (Cypex). Production of such 
large amounts of highly active human CYP enzymes in recombinant eukaryotic cells has never 
been reported before.  
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Figure 3. (A) Western blots of lysates of yeast cells expressing 2 copies of the CYP2D6-wt, CYP2D6.1, 
CYP2D6.10 and CYP2D6-C proteins, from the HIS3 and URA3 chromosomal loci of the strain YY7. 10 µg of total 
protein from ~1x 106 cells, obtained after lysis of the four strains (expressing 2 copies of each the four CYP2D6 
alleles), was probed with a CYP2D6 antibody (Panel A; Santa Cruz Biotechnology, sc-130366) and a β-actin 
antibody (Panel B; Proteintech, 60008-1-Ig). Lane 1, CYP2D6-wt; lane 2, CYP2D6.1; lane 3, CYP2D6.10; lane 4, 
CY2D6-C; lane 5, 0.3 pmole of CYP2D6-wt Sacchrosomes (i.e. microsomal CYP2D6-wt enzyme, isolated from 
baker’s yeast; CYP Design Ltd), as a positive control. (B-C) Calibration of CYP2D6 activities produced by 1x107 
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cells that express CYP2D6-wt (2D6-wt), CYP2D6-C (2D6-C) and CYP2D6.10 (2D6.10) proteins (B), using a 
standard curve (C) drawn using specific amounts (1, 1.5, 2 and 3 pmoles) of CYP2D6 Supersomes (Corning, 
#456217); CYP enzymes from Corning are widely considered to be the benchmark in the area of recombinant 
human CYP microsomal enzymes.  
 
Biotransformation of Codeine to Morphine by Baker’s Yeast Cells Expressing the 
CYP2D6-wt, CYP2D6.1, CYP2D6.10 and CYP2D6-C Enzymes. Using the four variant 
CYP2D6 enzymes, expressed in yeast from the four different CYP2D6 alleles, the metabolism 
of codeine to morphine was investigated. For the biotransformation reaction, 10 µM of codeine 
(final concentration) was added to each yeast cell culture that expressed different CYP2D6 
alleles. After completion of cell culture at defined time points (24, 48, 72 h), the media were 
extracted with an organic solvent, ethyl acetate. The residues obtained after evaporation of 
extracts were re-dissolved in 1 mL ethanol and then analyzed by TLC and HPLC.  
For TLC analyses, the equal volumes (5 µL) of the dissolved residues, obtained after 
extraction, were spotted on to TLC plates. The TLC images are shown in section S5 of the 
supporting information. Figure S5A shows that cells expressing CYP2D6.wild are hardly able 
to convert codeine to morphine. In contrast, CYP2D6-C, which is CYP2D6.10A112V produces 
more morphine than the other two CYP2D6 variant enzymes, CYP2D6-wt and CYP2D6.1. This 
is shown on the TLC plate in Figure S5B (lanes 5, 6 and 7) which also has as reference 
standards, codeine and its metabolites, i.e. morphine, norcodeine and normorphine (lanes 1-4). 
All cell culture extracts were then analyzed by HPLC, along with reference standards of codeine 
and its three metabolites, morphine, normorphine and norcodeine.26 Equal volumes of media 
extracts (10 µL), from the 72 h cultures, were injected into the HPLC column. HPLC results are 
shown in Figure 4 and the percentage of the metabolites formed are shown on the 
chromatograms. Data obtained from HPLC quantified the observations made with TLC. It was 
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confirmed that the CYP2D6-C enzyme, a variant of CYP2D6.10 (i.e. CYP2D6.10A112V), was 
superior in activity than the CYP2D6-wt and CYP2D6.1 enzymes, in the formation of morphine 
from codeine, although CYP2D6-C showed weaker activity compared with the other two 
variant enzymes when using EOMCC as a fluorogenic substrate (Figure 2C-D).  
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Figure 4. HPLC analysis of the biotransformation of codeine using three different CYP2D6 variant enzymes, 
CYP2D6-wt, CYP2D6.1 and CYP2D6-C (i.e. CYP2D6.10A122V) expressed within yeast. 10 µL of re-dissolved 
residues, obtained after extracting the reaction medium from 72 h cell cultures, was injected into the column. (A) to 
(D): HPLC chromatograms of codeine, morphine, normorphine and norcodeine which are reference standards. (E) 
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to (G): HPLC chromatograms of biotransformation reactions mediated by the CYP2D6 variants, CYP2D6-wt (E) 
CYP2D6.1 (F), CYP2D6C (G), using codeine as a substrate. The relative percentages of morphine, normorphine 
and norcodeine obtained from each CYP2D6-mediated reaction are shown on the chromatograms. The percentage 
values represent mean and standard deviations (± SD) from three independent experiments. In all experiments, 10 
µM (final concentration) of codeine was added to each yeast cell culture, bearing different CYP2D6 alleles.  
 
The results obtained from the biotransformation of codeine, using live yeast cells expressing 
different CYP2D6 alleles, clearly show that the CYP2D6-C (CYP2D6.10A112V) allele is more 
efficient in the conversion of codeine to morphine than the known extensive metabolizers 
CYP2D6.1 and CYP2D6-wt, although CYP2D6.10 is known to be a low metabolizer of 
codeine. This would suggest that the active site of the CYP2D6-C enzyme has a higher activity 
for the O-demethylation of codeine than the CYP2D6-wt and CYP2D6.1 enzymes.  
Molecular Modelling Studies. A total of ten crystal structures (one without any ligand and 
nine with a substrate or an inhibitor) have been reported.6, 27  The key sites in the CYP2D6 
enzyme that are utilized for demethylation of specific substrates have been established in the 
literature. Several site-directed mutagenesis and computational studies on the CYP2D6 cDNA 
and protein, respectively, have demonstrated that Glu 216, Asp 301, Phe 120 and Met 374 are 
key determinants of substrate specificity and product regioselectivity in CYP2D6.28 Because of 
the significant contribution of CYP2D6 in the metabolism of drugs, discovery of its inhibitors is 
a key research area in drug discovery programs.28d Furthermore, the CYP2D6 enzyme has 
extensively been studied for delineation of the metabolism (O-demethylation and N-
demethylation) of approved drugs viz metoprolol,29 gefitinib,30 and natural products.31 
In order to understand the observed trend in differential demethylation reactions (O versus N-
demethylation) using CYP2D6-wt and CYP2D6-C (CYP2D6.10A112V), molecular modelling 
studies were conducted. The crystal structure of CYP2D6.1 (PDB: 4WNW), comprising  
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thioridazine (CYP2D6 substrate) as a co-crystallized ligand, was selected. The required 
mutations were performed in Schrodinger to generate CYP2D6-wt (Val374Met) and CYP2D6-
C (Pro34Ser, Ser486Thr and Ala122Val) variants. The CYP2D6 structure has a well-defined 
active site cavity which is around 6-8  Å away from the haem group, and contains important 
residues that have been implicated in substrate recognition and binding. They include Asp-301, 
Glu-216, Phe-483, and Phe-120. The active site, where the substrate is accommodated, contains 
a hydrophobic binding pocket and comprises of residues Phe-110, Gly-244, Leu-248, Ile-297 
and Ala-300.6  The molecular docking of codeine with the active site of wild-type CYP2D6-wt 
(Figure 5a) shows that the hydrogen of the protonated nitrogen of codeine forms a H-bond with 
the carbonyl oxygen of Asp-301 (distance 2.24 Å). It has been reported in the literature that 
Asp-301 plays a key role in CYP2D6 mediated demethylation reactions.6 Thus, it is clear that 
the N-demethylation of codeine is mediated via its interaction with Asp-301. This observation 
supports the experimental results obtained with CYP2D6-wt, which favours N-demethylation to 
produce norcodeine as the major product. When Met (M) residue is substituted by Val (V) 
residue at position 374 in the CYP2D6.1 and CYP2D6.C amino acid sequence, the location of 
codeine is shifted towards haem along with a 90º flip, resulting in loss of a few crucial Van der 
Waals interactions with the residues at the hydrophobic binding cavity. In 2D6-C, the OMe 
group of codeine is present in close proximity to Val-374 (3.41 Å) and the OMe group 
containing Ar ring displays π-π interaction with Phe-120 residue. It has been reported that the 
374 residue has influence on cytochrome P450 expression, ligand binding, catalysis and 
functional activity of the CYP2D6 enzyme.32 The interaction of OMe group with Val 374 could 
be accounting for enhanced O-demethylation in case of 2D6-C in comparison to 2D6-wild. The 
interaction pattern of codeine in CYP2D6-C (i.e. CYP2D6.10A122V) is shown in Figures 5b. The 
docked images of thioridazine (CYP2D6 substrate) are provided in Figure S6a-c. 
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The interaction of EOMCC (7-ethoxy-methyloxy-3-cyanocoumarin), a substrate which is 
used in the biochemical assay, was also studied (Figure S7a-b). The interaction of CH2 with Glu 
216 is important for cleavage of ether bond (C-O-C bond) to form 7-hydroxy-3-cyanocoumarin 
metabolite, which is measured as an output of the assay, at excitation and emission wavelengths 
of 410 and 460 nM, respectively. In case of wild-type 2D6 (Met374), the CH2 group is closer to 
the Glu 216 (3.07 °A), in comparison to 2D-C (distance is 3.55 °A). This difference could be 
attributing to the lesser activity of EOMCC in case of 2D6-C variant in comparison to wild-type 
2D6.  
N-Me
O-Me
N-Me
O-Me
 
                                (a)       (b) 
Figure 5. The interaction pattern of codeine with CYP2D6-wt (a), and CYP2D6-C (CYP2D6.10A122V) (b). The 
pink dotted lines indicate specific distances between ligand and residues. 
 
CONCLUSIONS 
In summary, we have demonstrated that the CYP2D6.10 variant enzyme, CYP2D6.10A122V 
(CYP2D6-C), which has never been reported to exist in a human cDNA library, is a far superior 
metaboliser of codeine to morphine than the CYP2D6-wt (CYP2D6M374) or the CYP2D6.1 
(CYP2D6V374) enzymes. This result is quite unusual since published observations categorically 
show CYP2D6.10 as a low (i.e. weak) metabolizer of codeine to morphine. The enzyme 
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expressed from CYP2D6.10A122V yielded >70% of morphine from codeine in comparison to 
only ~30-35% of morphine using the other two variant enzymes, CYP2D6-wt and CYP2D6.1, 
which have been reported to be extensive metabolizers of codeine.2, 26  
Yeast cell-based systems, described in this report, are amenable to scale-up in fed-batch 
fermentors. Cells which individually express the newly identified CYP2D6 allele, 
CYP2D6.10A122V, and the CYP2D6-wt and CYP2D6.1 alleles, could find wider applicability in 
the identification, characterisation and large-scale isolation of CYP2D6-mediated formation of 
drug metabolites that would facilitate studies in the preclinical/clinical interface and in the 
clinic. They could also be used for regio-selective bioorganic syntheses of high-value natural 
products from more abundantly available chemicals available in nature.33  
 
EXPERIMENTAL SECTION 
Chemicals. Codeine, morphine, norcodeine and normorphine were bought from Sigma-
Aldrich on a license received by the Leicester School of Pharmacy, UK. All other chemicals 
used in this study were also obtained from Sigma-Aldrich.  
Gene Synthesis. The three CYP2D6 alleles, CYP2D6-wt (NCBI Accession No M20403 for 
DNA sequence; NCBI Accession No AAA52153 for debrisoquine 4-hydroxylase_Homo 
sapiens protein sequence;6 CYP2D6.1 (NCBI Accession No NM_000106 for DNA sequence; 
NCBI Accession No NP_000097 for protein sequence;34 and CYP2D6.10 (NCBI Accession No 
ABB01372), were chemically synthesized by Genewiz, USA. Tailor-made chemically 
synthesized genes are routinely used in molecular biology labs around the world.35 The 
synthesized genes for this manuscript were sourced from Genewiz (details can be obtained at 
https://www.genewiz.com/Public/Services/Gene-Synthesis).  
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Isolation of CYP2D6-C (CYP2D6.10A122V) cDNA. The CYP2D6-C cDNA was isolated by 
PCR using a human liver cDNA library, obtained from GATC Biotech (Germany), as template 
and CYP2D6-specific 5’ and 3’-end primers. The DNA of the isolated clone was confirmed by 
sequencing. The sequence was identical to the sequence of the TC104446 clone distributed by 
Origene (Rockville, Maryland, USA).  
Cloning of CYP2D6 Allelic Genes. The basic vectors (integrative plasmids used for 
chromosomal integration at the HIS3 and URA3 loci of baker’s yeast, Saccharomyces 
cerevisiae, and the episomal plasmid for extra-chromosomal replication), used for cloning of 
CYP2D6 gene expression cassettes, were obtained from CYP Design Ltd. The resultant 
plasmids, after cloning of CYP2D6 gene expression cassettes in respective vectors, were used 
for yeast transformation.  
Transformation of Yeast Cells. The yeast strain YY7, carrying the non-functional alleles 
ade2, leu2, his3, trp1 and ura3 which act as auxotrophic markers, already carried a modified 
less toxic version of the human P450 reductase (CPR) gene.25 Yeast transformation was carried 
out by the lithium acetate protocol.36 For integration of plasmids, bearing CYP2D6 alleles, into 
chromosomal locations where the HIS3 and URA3 genes exist (i.e. on chromosomes XV and V, 
respectively), the integrative plasmids were linearized with an appropriate restriction enzyme 
within the nutritional selection marker (HIS3 or URA3), in a way that at least 200 bps are at 
both the 5’ and 3’ segments of the fragmented gene, before the DNA was introduced into yeast 
cells. The linearized DNA underwent allelic homologous recombination23 with the genomic 
DNA at the chromosomal locations of the his3 or ura3 genes in the strain YY7.  
Growth of Cells for Comparison of Cellular CYP2D6 Enzyme Activities. Yeast strains, 
containing the CYP2D6 alleles, were at first streaked out on synthetic defined (SD) minimal 
medium agar plates (6.7 g/L yeast nitrogen base without amino acids; 20 g/L glucose; 20 g/L 
agar) with appropriate nutrients depending on the auxotroph. The plates were incubated for 3 
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days at 30 °C. Three individual colonies were inoculated into in 5 mL of SD medium (6.7 g/L 
yeast nitrogen base without amino acids; 20 g/L glucose) containing appropriate nutrients. Cells 
were grown for 20 h at 30°C in an orbital shaker at 220 rpm. 0.1 OD600 (optical density of cells 
measured at 600 nm) of cells from the minimal medium SD pre-cultures were inoculated into 5 
mL of full (non-selective) YPD medium (10 g/L yeast extract; 20 g/L peptone; 20 g/L glucose) 
for expression of the CYP2D6 alleles, and grown overnight for 18 h at 30ºC. At this time point, 
the cells were still in the late exponential growth phase (thus preventing the decay of CYP 
enzyme activity that occurs at the stationary phase), and glucose in the medium was fully 
exhausted. Cells were counted so that exactly the same number of cells were used for all 
fluorescence-based CYP2D6 enzyme activity assays.  
Determination of Cellular CYP2D6 Enzyme Activities. 1 x 107 (~1 OD600) cells were 
aliquoted into Eppendorf tubes and centrifuged for 1 min on a bench-top centrifuge. The pellets 
were resuspended in 500 µL 1x TE (50 mM Tris-HCl, 1 mM EDTA, pH.7.4) and centrifuged 
for 1 min. This was repeated twice. The supernatants were removed carefully and the pellets 
were finally resuspended in 500 µL of 1x TE. 50 µL of cell suspensions were transferred into a 
sterile 96-well microtiter plate to which 50 µL of a 4 µM EOMCC (7-ethoxymethoxy-3-
cyanocoumarin) containing solution was added. Plates were incubated at 30 °C for 30 min 
before the fluorescence excitation/emissions of the CYP2D6-mediated fluorescent product, 7-
HCC (7-hydroxy-3-cyanocoumarin), were monitored at 410/460 nm on a fluorescence plate 
reader (Synergy HT BioTek), over a period of time. The gain sensitivities of the plate reader 
were set in a way that allowed the best kinetic output to be obtained. The plates were incubated 
at 30°C for 30 secs before the fluorescence emissions were measured.  
Western Blotting. 1x 107 cells, bearing CYP2D6 alleles, after growth in YPD medium for 
18 h at 30 ºC, were harvested. TE-washed cells were suspended in 200 µL of SDS-TE buffer 
(5.7 µL 10X SDS, 1 mL 10X TE buffer, made up to 10 mL with deionized pure water). The cell 
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suspension was sonicated (Grant Ultrasonic bath XUBA1), twice for 10 secs, and then 
incubated at 95°C for 10 min. Proteins in the supernatants were estimated via Lowry’s method 
(Pierce; Thermo Fisher Scientific) and were diluted 1:10 in SDS sample buffer before loading 
on a 7.5% SDS-polyacrylamide gel for electrophoresis.  
Biotransformation Experiments. Strains, containing a chromosomally integrated CYP2D6 
allele (one or two copies), or an episomal plasmid bearing a CYP2D6 gene expression cassette, 
were revived on YPD plates. Typically, a loopful of CYP2D6-containing freshly grown yeast 
cells was inoculated in a 500 mL Erlenmeyer baffled flask containing 100 mL YPD medium 
(pre-culture-1) at 28°C for 24 h. Baffled flasks allow vigorous aeration. The cells were 
harvested after 24 h and inoculated into a new 500 mL baffled flask containing 100 mL YPD 
medium (pre-culture-2) at 30 °C for 18 h. The process was repeated a third time (pre-culture-3) 
for the cells to reach an OD600, of ~90/mL. 100 OD600 of cells from pre-culture-3 were 
resuspended in 25 mL of SD medium contained in a 250 ml baffled flask. A final concentration 
of 10 µM codeine was added to the cultures. Flasks were shaken at 30°C, 220 rpm, for 24, 48, 
and 72 h. Cells were harvested every 24 h for assessing biotransformation (i.e. for amounts of 
formed products). After every 24 h of growth, 1 mL of 50% glucose was added to the 25 mL 
cultures to replenish levels of glucose to 2%. The SD reaction medium was extracted with ethyl 
acetate (3 times). The combined ethyl acetate layer was concentrated on vacuo-rotavapor to 
obtain residues that contained the biotransformation products. The residues, re-dissolved in 1 ml 
of ethanol, were analyzed on TLC plates and with HPLC.  
TLC Analysis. Equal volumes (5 µL) of the re-dissolved residue, obtained after extraction of 
the reaction media, were spotted on to lanes of TLC plates (Sigma Aldrich # Z193275-1). For 
TLC detection of codeine and its metabolites formed in the biotransformation experiments, the 
solvent system was CHCl3: MeOH: NH3 = 36:1:0.6. 
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HPLC Analysis. HPLC analysis was performed on a Shimadzu LC-6AD system connected 
with a C18 column (4.6 x 25 mm, 5 µ). Mobile phase consisted of A: 0.1% formic acid and B: 
methanol using isocratic elution (30: 70 – A: B). Flow rate was 1 mL/min. Detection 
wavelength was 270 nm. The crude residue, obtained after extraction of the reaction media, was 
loaded on a reverse phase (C18) silica gel column packed in water. The crude extract was 
loaded on the column by making slurry with C18 silica gel. The column was then eluted with 
increasing concentrations of methanol in water.  
Molecular Modelling: The docking of codeine with CYP2D6 (PDB ID: 4WNT) was 
performed using GLIDE module of Schrodinger molecular modelling software, using the 
protocols as described in our earlier publications.37 The docking protocol was validated by re-
docking known ligand ajmalicine. The interaction pattern of docked ajmalicine and ligand from 
co-crystallized protein (4WNT) are shown in the Supporting Information.  
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